New Research Unveils Faulty Ion Channel Linked to ME/CFS

A recent study conducted by researchers at Griffith University has identified a faulty ion channel in immune cells of individuals diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). This discovery offers critical validation for the many Australians suffering from this debilitating condition, which has long been misunderstood and stigmatized.

The research, led by Professor Sonya Marshall-Gradisnik from Griffith’s National Centre for Neuroimmunology and Emerging Diseases (NCNED), revealed that the TRPM3 ion channel, which is essential for calcium transport into cells, is dysfunctional in ME/CFS patients. Professor Marshall-Gradisnik emphasized the importance of calcium signalling in maintaining effective immune function and overall cellular health. She stated, “When it fails, cells cannot function properly as calcium signalling is essential for healthy immune cell activity.”

Using a highly reliable technique, the research team demonstrated a significant and reproducible reduction in TRPM3 activity in the immune cells of ME/CFS patients when compared to healthy individuals. This finding was consistent across different laboratories, including one located over 4,000 kilometres away, highlighting the robustness of the results.

Scientific Breakthrough Validates Patient Experiences

Lead author Dr Etianne Sasso remarked that this discovery not only contributes to global scientific understanding of ME/CFS but also validates the experiences of patients who have faced skepticism regarding their condition. “These results provide further evidence for developing a diagnostic test for ME/CFS and will also guide us toward new therapeutic targets,” she noted. The hope is that this research will ultimately lead to effective treatments that can enhance cellular function and improve the quality of life for those affected.

Dr Sasso elaborated on the implications of the findings, explaining, “The faulty ion channels act like ‘stuck doors’, preventing cells from receiving the calcium they need.” This dysfunction contributes to the myriad symptoms of ME/CFS, which can include severe fatigue, pain, cognitive difficulties, and disruptions in daily activities.

Clinician Dr Peter Smith, who treats patients with ME/CFS, highlighted the significance of the findings. “This research provides concrete biological evidence that supports what patients have been describing for decades,” he stated. Dr Smith believes that recognizing this measurable cellular dysfunction affirms ME/CFS as a legitimate medical condition, enhancing confidence in patient care and fostering hope for future treatment options.

Study Context and Future Directions

The study was conducted across independent laboratory sites in Gold Coast and Perth, involving participants from South East Queensland, North East New South Wales, and Western Australia. It received funding from the National Health and Medical Research Council of Australia and the Stafford Fox Medical Research Foundation.

The findings were published in the journal Frontiers in Medicine in 2026, underscoring the ongoing commitment to understanding and addressing ME/CFS. The study marks a pivotal moment in the recognition of the biological underpinnings of this condition, which affects a significant number of individuals worldwide.

As researchers continue to explore the implications of these findings, the hope is that they will pave the way for new diagnostic tools and treatment strategies, ultimately improving the lives of those living with ME/CFS.